Lineage Therap (LCTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $9.00 price target.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding the promising advancements in Lineage Cell Therapeutics’ OPC1 program. The commencement of the Phase 2 DOSED study marks a significant milestone as OPC1 returns to clinical trials, emphasizing enhancements in the delivery system for spinal cord injury patients. This study aims to improve upon previous positive clinical outcomes by using a new device that simplifies the procedure and enhances patient safety.
The foundation for optimism is based on successful results from earlier trials, where OPC1 demonstrated safety and efficacy in both thoracic and cervical spinal cord injury patients. These trials showed no neurological decline and notable motor improvements over extended follow-up periods. The upcoming trial updates and potential additional funding further bolster investor confidence in Lineage’s lead asset, which is expected to generate significant clinical data, supporting Pantginis’s positive outlook on the stock.
According to TipRanks, Pantginis is an analyst with an average return of -4.1% and a 28.96% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Esperion, and Viking Therapeutics.